PRN Archives | BioTuesdays

Developments

Profound Medical implements share consolidation for proposed NASDAQ listing

Profound Medical (TSX:PRN; OTCQX:PRFMF) implemented a one-for-10 consolidation of its shares outstanding to qualify for a potential listing on The NASDAQ Stock Market. Shareholders approved the consolidation at the...

October 11, 2019

Markets

Raymond James starts Profound Medical at OP; PT $4

Raymond James initiated coverage of Profound Medical (TSX:PRN; OTCQX:PRFMF) with an “outperform” rating and price target of $4. The stock closed at 92 cents on Aug. 23. “With its highly experienced management team...

August 26, 2019

Developments

Profound Medical gets FDA clearance to market TULSA-PRO for the treatment of prostate disease

Profound Medical (TSX:PRN; OTCQX:PRFMF) received FDA clearance to market TULSA-PRO for the ablation of prostate tissue, with an FDA label allowing U.S. surgeons to perform procedures on both malignant and benign tissue...

August 16, 2019

Executive Moves

Profound Medical names senior finance executive, Steve Forte, to board

Profound Medical (TSX:PRN; OTCQX:PRFMF) appointed seasoned cross-border finance leader, Steve Forte, as a director and member of the board’s audit committee. Most recently, Mr. Forte was CFO of Clementia Pharmaceuticals...

August 15, 2019

Executive Moves

Profound Medical appoints Ian Heynen as SVP sales and marketing

Profound Medical (TSXV:PRN; OTCQX:PRFMF) appointed Ian Heynen as SVP of sales and marketing.

April 23, 2018

Developments

Profound Medical Q2 Top Pick at Paradigm Capital

Paradigm Capital has made Profound Medical (TSXV:PRN; OTCQX:PRFMF) its second quarter Top Pick, saying the next three-to-four months are expected to be an accretive time for Profound.

April 12, 2018

Markets

Paradigm ups Profound Medical PT to $3

Paradigm Capital raised its price target for Profound Medical (TSXV:PRN) to $3 from $2.25 after the company completed an upsized equity financing of $34.5-million. The stock closed at $1.05 on March 20.

March 21, 2018

Markets

Profound Medical closes upsized bought deal financing

Profound Medical (TSXV:PRN) closed a previously announced bought deal financing for gross proceeds of $34.5-million, including the exercise of the underwriters’ over-allotment option.

March 20, 2018

Features

Profound makes leap to platform company from prostate product

With its recent acquisition of Royal Philips’ (NYSE:PHG; AEX:PHIA) Sonalleve business, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is making the leap from a medical device company focused on prostate cancer ablation to a...

September 5, 2017

Features

Profound Medical’s TULSA-PRO pilot OUS launch: paving the way for global growth

After nearly a decade of R&D, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is now conducting a pilot launch of its TULSA-PRO medical device to ablate tissue in localized prostate cancer within key European and other CE...

March 28, 2017

Tag - PRN

Profound Medical implements share consolidation for proposed NASDAQ listing

Raymond James starts Profound Medical at OP; PT $4

Profound Medical gets FDA clearance to market TULSA-PRO for the treatment of prostate disease

Profound Medical names senior finance executive, Steve Forte, to board

Profound Medical appoints Ian Heynen as SVP sales and marketing

Profound Medical Q2 Top Pick at Paradigm Capital

Paradigm ups Profound Medical PT to $3

Profound Medical closes upsized bought deal financing

Profound makes leap to platform company from prostate product

Profound Medical’s TULSA-PRO pilot OUS launch: paving the way for global growth

Follow Us

Subscribe

General

More

Subscribe